论文部分内容阅读
目的:比较分析放疗合并DDP化疗与单纯放疗对Ⅲ期宫颈癌术后患者的临床疗效。方法:选择2008年2月至2013年5月于我院接受治疗的97例Ⅲ期宫颈癌术后患者作为研究对象,根据化疗方式的不同分为合并放化疗组(n=50例)和单纯放疗组(n=47例)。合并放化疗组采用放疗同步每周予DDP增敏化疗。单纯放疗组患者在术后仅采取放疗方式,所有患者均行辅助化疗(TP方案)及术后盆腔放疗。对比两组患者比较两组患者的近期疗效、毒副反应发生情况和1年以及3年生存率。结果:两组患者在近期治疗效果方面并没有显著性差异(P>0.05),合并放化疗组患者的毒副反应发生情况显著高于单纯放疗组患者(P<0.05),合并放化疗组患者1年以及3年生存率显著高于单纯放疗组患者(P<0.05)。结论:放疗合并DDP化疗可显著提升Ⅲ期宫颈癌术后患者的1年以及3年生存率,虽然存在较为明显的毒副反应情况,但患者均能耐受,从远期疗效来看,放疗合并DDP化疗在临床治疗中可行。
Objective: To compare and analyze the clinical effects of radiotherapy combined with DDP chemotherapy and radiotherapy alone for postoperative patients with stage Ⅲ cervical cancer. Methods: A total of 97 patients with stage Ⅲ cervical cancer who were treated in our hospital from February 2008 to May 2013 were selected as study subjects. Patients were divided into chemotherapy group (n = 50) and simple chemotherapy group Radiotherapy group (n = 47). Radiotherapy combined with radiotherapy and chemotherapy group weekly synchronized DDP sensitization chemotherapy. Patients in the radiotherapy group only received radiotherapy after operation. All patients received adjuvant chemotherapy (TP regimen) and pelvic radiotherapy after operation. The two groups were compared the two groups of patients with short-term efficacy, the incidence of side effects and 1 year and 3 year survival rate. Results: There was no significant difference between the two groups in the short term therapeutic effect (P> 0.05). The incidence of side effects in patients receiving radiotherapy and chemotherapy was significantly higher than that in radiotherapy alone group (P <0.05) The 1-year and 3-year survival rates were significantly higher than those in radiotherapy alone group (P <0.05). Conclusion: Radiotherapy combined with DDP chemotherapy can significantly improve the 1-year and 3-year survival rate of patients with stage III cervical cancer after operation. Although there are obvious side effects, patients can tolerate. In terms of long-term efficacy, radiotherapy Combined DDP chemotherapy in the clinical treatment feasible.